Novavax (NVAX) Shares Outstanding (Weighted Average) (2010 - 2026)

Novavax's Shares Outstanding (Weighted Average) history runs 17 years deep, the most recent figure standing at $163.3 million for Q1 2026.

• In Q1 2026, Shares Outstanding (Weighted Average) rose 1.38% year-over-year to $163.3 million; the TTM figure through Mar 2026 stood at $163.3 million (up 1.38% YoY), while the FY2025 annual figure was $162.0 million, up 6.44% from the prior year.
• Shares Outstanding (Weighted Average) was $163.3 million for Q1 2026 at Novavax, up from $162.0 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $163.3 million in Q1 2026 to a low of $76.5 million in Q1 2022.
• Historically, Shares Outstanding (Weighted Average) has averaged $122.7 million across 5 years, with a median of $139.9 million in 2024.
• The sharpest annual moves came in 2024 and 2026: Shares Outstanding (Weighted Average) jumped 62.39% in 2024, then climbed 1.38% in 2026.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $78.2 million in 2022, then advanced by 28.89% to $100.8 million in 2023, then jumped by 51.03% to $152.2 million in 2024, then gained by 6.44% to $162.0 million in 2025, then rose by 0.79% to $163.3 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $163.3 million (Q1 2026), $162.0 million (Q4 2025), and $161.8 million (Q3 2025), per Business Quant data.